

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 39 (canceled).

Claim 40 (currently amended): An antibody covalently attached to a target polypeptide having an amino acid sequence heterologous to the antibody wherein the target polypeptide comprises four cysteine residues which together are capable of specifically reacting with a single biarsenical molecule having the formula:

~~A polypeptide comprising a carrier polypeptide, or a fragment thereof, and a target amino acid sequence heterologous to the amino acid sequence of the carrier polypeptide wherein the target amino acid sequence comprises one or more cysteines which specifically react with a biarsenical molecule having the following formula~~



Claim 41 (currently amended): The antibody polypeptide of claim 40 [[1]], wherein a ~~polypeptide domain comprising~~ the target polypeptide amino acid sequence is covalently attached to ~~a~~ the N-terminus of the antibody carrier polypeptide.

Claim 42 (currently amended): The antibody polypeptide of claim 40 [[1]], wherein a ~~polypeptide domain comprising~~ the target polypeptide amino acid sequence is covalently attached to ~~a~~ the C-terminus of the antibody carrier polypeptide.

Claim 43 (currently amended): The antibody polypeptide of claim 40 [[1]], wherein the antibody ~~carrier polypeptide~~ is divided into a first portion and a second portion and the target polypeptide ~~amino acid sequence~~ is located therebetween.

Claim 44 (currently amended): The antibody polypeptide of claim 40 [[1]], wherein the target polypeptide amino acid sequence comprises four cysteines in an α -helical domain.

Claim 45 (currently amended): The antibody polypeptide of claim 40 [[1]], wherein a ~~polypeptide domain comprising~~ the target polypeptide amino acid sequence comprises an α -helical domain having a -cys-cys-X-Y-cys-cys- sequence, wherein X and Y are amino acids.

Claims 46 to 47 (canceled).

Claim 48 (currently amended): The antibody polypeptide of claim 40 [[1]], wherein the target polypeptide sequence is at least 6 amino acids in length.

Claim 49 (currently amended): The antibody polypeptide of claim 40 [[1]], wherein the target polypeptide sequence is at least 10 amino acids in length.

Claim 50 (currently amended): The antibody ~~polypeptide~~ of claim 40 [[1]], wherein ~~further~~ the target polypeptide has an N-terminal amino acid which is acetylated.

Claim 51 (currently amended): The antibody ~~polypeptide~~ of claim 40 [[1]], wherein the target polypeptide has a C-terminal amino acid which is amidated.

Claim 52 (currently amended): The antibody ~~polypeptide~~ of claim 40 [[1]], wherein ~~further~~ the target polypeptide has an N-terminal amino acid which is acetylated and a C-terminal amino acid which is amidated.

Claim 53 (currently amended): The antibody ~~polypeptide~~ of claim 52, wherein the target polypeptide ~~sequence~~ comprises the amino acid sequence of SEQ ID NO:1.

Claim 54 (new): The antibody of claim 40, wherein the antibody and the target polypeptide together form a fusion polypeptide.

Claim 55 (new): The antibody of claim 40, wherein the target polypeptide consists essentially of the peptide of SEQ ID NO:2.